Neuroendocrine tumors

Clinical Practice Guidelines in Oncology™

Orlo H. Clark, Jaffer Ajani, Al B. Benson, David Byrd, Gerard M. Doherty, Paul F. Engstrom, David S Ettinger, John F. Gibbs, Martin J. Heslin, Fouad Kandeel, Anne Kessinger, Matthew H. Kulke, Larry Kvols, Albert A. Nemcek, John A. Olson, Thomas W. Ratliff, Leonard Saltz, David E. Schteingart, Manisha H. Shah, Stephen Shibata

Research output: Contribution to journalArticle

Abstract

Neuroendocrine tumors are relatively rare. An estimated 25,690 new cases of thyroid cancer will be diagnosed in the United States in 2005, accounting for approximately 1% of all malignancies. Neuroendocrine tumors can be broadly subdivided into tumors that are benign or malignant, functional (i.e., producing a syndrome of hormonal excess) or nonfunctional. The management of neuroendocrine tumors with surgical, medical, or radiation therapies is determined by the specific endocrine glands involved, aggressiveness and stage of the tumor, hormonal concentrations detected, and specific patient needs. These guidelines have been designed to address scenarios presented by 80% of patients and to avoid scenarios relevant to less than 5% of patients.

Original languageEnglish (US)
Pages (from-to)102-138
Number of pages37
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume4
Issue number2
StatePublished - Feb 2006

Fingerprint

Neuroendocrine Tumors
Practice Guidelines
Endocrine Glands
Neoplasms
Thyroid Neoplasms
Radiotherapy
Guidelines

Keywords

  • Carcinoma
  • Islet cell cancer
  • MEN-1
  • MEN-2
  • Multiple endocrine neoplasia
  • NCCN Clinical Practice Guidelines
  • Neuroendocrine tumors
  • Pheochromocytoma

ASJC Scopus subject areas

  • Oncology

Cite this

Clark, O. H., Ajani, J., Benson, A. B., Byrd, D., Doherty, G. M., Engstrom, P. F., ... Shibata, S. (2006). Neuroendocrine tumors: Clinical Practice Guidelines in Oncology™. JNCCN Journal of the National Comprehensive Cancer Network, 4(2), 102-138.

Neuroendocrine tumors : Clinical Practice Guidelines in Oncology™. / Clark, Orlo H.; Ajani, Jaffer; Benson, Al B.; Byrd, David; Doherty, Gerard M.; Engstrom, Paul F.; Ettinger, David S; Gibbs, John F.; Heslin, Martin J.; Kandeel, Fouad; Kessinger, Anne; Kulke, Matthew H.; Kvols, Larry; Nemcek, Albert A.; Olson, John A.; Ratliff, Thomas W.; Saltz, Leonard; Schteingart, David E.; Shah, Manisha H.; Shibata, Stephen.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 4, No. 2, 02.2006, p. 102-138.

Research output: Contribution to journalArticle

Clark, OH, Ajani, J, Benson, AB, Byrd, D, Doherty, GM, Engstrom, PF, Ettinger, DS, Gibbs, JF, Heslin, MJ, Kandeel, F, Kessinger, A, Kulke, MH, Kvols, L, Nemcek, AA, Olson, JA, Ratliff, TW, Saltz, L, Schteingart, DE, Shah, MH & Shibata, S 2006, 'Neuroendocrine tumors: Clinical Practice Guidelines in Oncology™', JNCCN Journal of the National Comprehensive Cancer Network, vol. 4, no. 2, pp. 102-138.
Clark OH, Ajani J, Benson AB, Byrd D, Doherty GM, Engstrom PF et al. Neuroendocrine tumors: Clinical Practice Guidelines in Oncology™. JNCCN Journal of the National Comprehensive Cancer Network. 2006 Feb;4(2):102-138.
Clark, Orlo H. ; Ajani, Jaffer ; Benson, Al B. ; Byrd, David ; Doherty, Gerard M. ; Engstrom, Paul F. ; Ettinger, David S ; Gibbs, John F. ; Heslin, Martin J. ; Kandeel, Fouad ; Kessinger, Anne ; Kulke, Matthew H. ; Kvols, Larry ; Nemcek, Albert A. ; Olson, John A. ; Ratliff, Thomas W. ; Saltz, Leonard ; Schteingart, David E. ; Shah, Manisha H. ; Shibata, Stephen. / Neuroendocrine tumors : Clinical Practice Guidelines in Oncology™. In: JNCCN Journal of the National Comprehensive Cancer Network. 2006 ; Vol. 4, No. 2. pp. 102-138.
@article{97f04c7a23da408ab7f5b9e6ee9ce9c7,
title = "Neuroendocrine tumors: Clinical Practice Guidelines in Oncology™",
abstract = "Neuroendocrine tumors are relatively rare. An estimated 25,690 new cases of thyroid cancer will be diagnosed in the United States in 2005, accounting for approximately 1{\%} of all malignancies. Neuroendocrine tumors can be broadly subdivided into tumors that are benign or malignant, functional (i.e., producing a syndrome of hormonal excess) or nonfunctional. The management of neuroendocrine tumors with surgical, medical, or radiation therapies is determined by the specific endocrine glands involved, aggressiveness and stage of the tumor, hormonal concentrations detected, and specific patient needs. These guidelines have been designed to address scenarios presented by 80{\%} of patients and to avoid scenarios relevant to less than 5{\%} of patients.",
keywords = "Carcinoma, Islet cell cancer, MEN-1, MEN-2, Multiple endocrine neoplasia, NCCN Clinical Practice Guidelines, Neuroendocrine tumors, Pheochromocytoma",
author = "Clark, {Orlo H.} and Jaffer Ajani and Benson, {Al B.} and David Byrd and Doherty, {Gerard M.} and Engstrom, {Paul F.} and Ettinger, {David S} and Gibbs, {John F.} and Heslin, {Martin J.} and Fouad Kandeel and Anne Kessinger and Kulke, {Matthew H.} and Larry Kvols and Nemcek, {Albert A.} and Olson, {John A.} and Ratliff, {Thomas W.} and Leonard Saltz and Schteingart, {David E.} and Shah, {Manisha H.} and Stephen Shibata",
year = "2006",
month = "2",
language = "English (US)",
volume = "4",
pages = "102--138",
journal = "Journal of the National Comprehensive Cancer Network : JNCCN",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "2",

}

TY - JOUR

T1 - Neuroendocrine tumors

T2 - Clinical Practice Guidelines in Oncology™

AU - Clark, Orlo H.

AU - Ajani, Jaffer

AU - Benson, Al B.

AU - Byrd, David

AU - Doherty, Gerard M.

AU - Engstrom, Paul F.

AU - Ettinger, David S

AU - Gibbs, John F.

AU - Heslin, Martin J.

AU - Kandeel, Fouad

AU - Kessinger, Anne

AU - Kulke, Matthew H.

AU - Kvols, Larry

AU - Nemcek, Albert A.

AU - Olson, John A.

AU - Ratliff, Thomas W.

AU - Saltz, Leonard

AU - Schteingart, David E.

AU - Shah, Manisha H.

AU - Shibata, Stephen

PY - 2006/2

Y1 - 2006/2

N2 - Neuroendocrine tumors are relatively rare. An estimated 25,690 new cases of thyroid cancer will be diagnosed in the United States in 2005, accounting for approximately 1% of all malignancies. Neuroendocrine tumors can be broadly subdivided into tumors that are benign or malignant, functional (i.e., producing a syndrome of hormonal excess) or nonfunctional. The management of neuroendocrine tumors with surgical, medical, or radiation therapies is determined by the specific endocrine glands involved, aggressiveness and stage of the tumor, hormonal concentrations detected, and specific patient needs. These guidelines have been designed to address scenarios presented by 80% of patients and to avoid scenarios relevant to less than 5% of patients.

AB - Neuroendocrine tumors are relatively rare. An estimated 25,690 new cases of thyroid cancer will be diagnosed in the United States in 2005, accounting for approximately 1% of all malignancies. Neuroendocrine tumors can be broadly subdivided into tumors that are benign or malignant, functional (i.e., producing a syndrome of hormonal excess) or nonfunctional. The management of neuroendocrine tumors with surgical, medical, or radiation therapies is determined by the specific endocrine glands involved, aggressiveness and stage of the tumor, hormonal concentrations detected, and specific patient needs. These guidelines have been designed to address scenarios presented by 80% of patients and to avoid scenarios relevant to less than 5% of patients.

KW - Carcinoma

KW - Islet cell cancer

KW - MEN-1

KW - MEN-2

KW - Multiple endocrine neoplasia

KW - NCCN Clinical Practice Guidelines

KW - Neuroendocrine tumors

KW - Pheochromocytoma

UR - http://www.scopus.com/inward/record.url?scp=33646825000&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646825000&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 102

EP - 138

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

SN - 1540-1405

IS - 2

ER -